190 related articles for article (PubMed ID: 32035011)
1. Inclusion-body myositis and primary Sjögren syndrome: mechanisms for shared etiologies.
Limaye VS; Cash K; Smith C; Koszyca B; Patel S; Greenberg SA; Hissaria P
Muscle Nerve; 2020 May; 61(5):570-574. PubMed ID: 32035011
[TBL] [Abstract][Full Text] [Related]
2. The association of sporadic inclusion body myositis and Sjögren's syndrome in carriers of HLA-DR3 and the 8.1 MHC ancestral haplotype.
Rojana-udomsart A; Needham M; Luo YB; Fabian V; Walters S; Zilko PJ; Mastaglia FL
Clin Neurol Neurosurg; 2011 Sep; 113(7):559-63. PubMed ID: 21507567
[TBL] [Abstract][Full Text] [Related]
3. Anti-cN1A antibodies do not correlate with specific clinical, electromyographic, or pathological findings in sporadic inclusion body myositis.
Paul P; Liewluck T; Ernste FC; Mandrekar J; Milone M
Muscle Nerve; 2021 Apr; 63(4):490-496. PubMed ID: 33373040
[TBL] [Abstract][Full Text] [Related]
4. Pathomechanisms of anti-cytosolic 5'-nucleotidase 1A autoantibodies in sporadic inclusion body myositis.
Tawara N; Yamashita S; Zhang X; Korogi M; Zhang Z; Doki T; Matsuo Y; Nakane S; Maeda Y; Sugie K; Suzuki N; Aoki M; Ando Y
Ann Neurol; 2017 Apr; 81(4):512-525. PubMed ID: 28318044
[TBL] [Abstract][Full Text] [Related]
5. Significance of Sjögren's syndrome and anti-cN1A antibody in myositis patients.
Levy D; Nespola B; Giannini M; Felten R; Severac F; Varoquier C; Rinagel M; Korganow AS; Martin T; Poindron V; Maurier F; Chereih H; Bouldoires B; Hervier B; Lenormand C; Chatelus E; Geny B; Sibilia J; Arnaud L; Gottenberg JE; Meyer A
Rheumatology (Oxford); 2022 Feb; 61(2):756-763. PubMed ID: 33974078
[TBL] [Abstract][Full Text] [Related]
6. Autoantibodies to cytosolic 5'-nucleotidase 1A in inclusion body myositis.
Pluk H; van Hoeve BJ; van Dooren SH; Stammen-Vogelzangs J; van der Heijden A; Schelhaas HJ; Verbeek MM; Badrising UA; Arnardottir S; Gheorghe K; Lundberg IE; Boelens WC; van Engelen BG; Pruijn GJ
Ann Neurol; 2013 Mar; 73(3):397-407. PubMed ID: 23460448
[TBL] [Abstract][Full Text] [Related]
7. [Sporadic Inclusion Body Myositis and Autoantibodies].
Yamashita S; Ando Y
Brain Nerve; 2018 Apr; 70(4):449-457. PubMed ID: 29632292
[TBL] [Abstract][Full Text] [Related]
8. Anti-NT5c1A Autoantibodies as Biomarkers in Inclusion Body Myositis.
Amlani A; Choi MY; Tarnopolsky M; Brady L; Clarke AE; Garcia-De La Torre I; Mahler M; Schmeling H; Barber CE; Jung M; Fritzler MJ
Front Immunol; 2019; 10():745. PubMed ID: 31024569
[No Abstract] [Full Text] [Related]
9. Sporadic inclusion body myositis and primary Sjogren's syndrome: an overlooked diagnosis.
Chung SH; Bent EI; Weiss MD; Gardner GC
Clin Rheumatol; 2021 Oct; 40(10):4089-4094. PubMed ID: 33884496
[TBL] [Abstract][Full Text] [Related]
10. Autoantibodies to Cytosolic 5'-Nucleotidase 1A in Primary Sjögren's Syndrome and Systemic Lupus Erythematosus.
Rietveld A; van den Hoogen LL; Bizzaro N; Blokland SLM; Dähnrich C; Gottenberg JE; Houen G; Johannsen N; Mandl T; Meyer A; Nielsen CT; Olsson P; van Roon J; Schlumberger W; van Engelen BGM; Saris CGJ; Pruijn GJM
Front Immunol; 2018; 9():1200. PubMed ID: 29922285
[TBL] [Abstract][Full Text] [Related]
11. Disease specificity of autoantibodies to cytosolic 5'-nucleotidase 1A in sporadic inclusion body myositis versus known autoimmune diseases.
Herbert MK; Stammen-Vogelzangs J; Verbeek MM; Rietveld A; Lundberg IE; Chinoy H; Lamb JA; Cooper RG; Roberts M; Badrising UA; De Bleecker JL; Machado PM; Hanna MG; Plestilova L; Vencovsky J; van Engelen BG; Pruijn GJ
Ann Rheum Dis; 2016 Apr; 75(4):696-701. PubMed ID: 25714931
[TBL] [Abstract][Full Text] [Related]
12. Cytosolic 5'-nucleotidase 1A autoimmunity in sporadic inclusion body myositis.
Larman HB; Salajegheh M; Nazareno R; Lam T; Sauld J; Steen H; Kong SW; Pinkus JL; Amato AA; Elledge SJ; Greenberg SA
Ann Neurol; 2013 Mar; 73(3):408-18. PubMed ID: 23596012
[TBL] [Abstract][Full Text] [Related]
13. Sensitivity and clinical utility of the anti-cytosolic 5'-nucleotidase 1A (cN1A) antibody test in sporadic inclusion body myositis: Report of 40 patients from a single neuromuscular center.
Felice KJ; Whitaker CH; Wu Q; Larose DT; Shen G; Metzger AL; Barton RW
Neuromuscul Disord; 2018 Aug; 28(8):660-664. PubMed ID: 30001928
[TBL] [Abstract][Full Text] [Related]
14. Seropositivity for NT5c1A antibody in sporadic inclusion body myositis predicts more severe motor, bulbar and respiratory involvement.
Goyal NA; Cash TM; Alam U; Enam S; Tierney P; Araujo N; Mozaffar FH; Pestronk A; Mozaffar T
J Neurol Neurosurg Psychiatry; 2016 Apr; 87(4):373-8. PubMed ID: 25857661
[TBL] [Abstract][Full Text] [Related]
15. Determination of cN1A Autoantibodies by Cell-Based Immunofluorescence Cytochemistry.
Yamashita S; Tawara N
Methods Mol Biol; 2019; 1901():89-94. PubMed ID: 30539570
[TBL] [Abstract][Full Text] [Related]
16. Pathogenic role of anti-cN1A autoantibodies in sporadic inclusion body myositis.
Yamashita S; Tawara N; Zhang Z; Nakane S; Sugie K; Suzuki N; Nishino I; Aoki M
J Neurol Neurosurg Psychiatry; 2023 Dec; 94(12):1018-1024. PubMed ID: 37451693
[TBL] [Abstract][Full Text] [Related]
17. Association of inclusion body myositis with T cell large granular lymphocytic leukaemia.
Greenberg SA; Pinkus JL; Amato AA; Kristensen T; Dorfman DM
Brain; 2016 May; 139(Pt 5):1348-60. PubMed ID: 26920676
[TBL] [Abstract][Full Text] [Related]
18. [Primary Sjögren syndrome and inclusion body myositis].
Monteiro P; Coutinho M; Salvador MJ; Malcata A
Acta Reumatol Port; 2009; 34(2A):261-5. PubMed ID: 19474780
[TBL] [Abstract][Full Text] [Related]
19. Novel serology testing for sporadic inclusion body myositis: disease-specificity and diagnostic utility.
Herbert MK; Pruijn GJ
Curr Opin Rheumatol; 2015 Nov; 27(6):595-600. PubMed ID: 26285103
[TBL] [Abstract][Full Text] [Related]
20. Refining myositis associated with primary Sjögren's syndrome: data from the prospective cohort ASSESS.
Felten R; Giannini M; Nespola B; Lannes B; Levy D; Seror R; Vittecoq O; Hachulla E; Perdriger A; Dieude P; Dubost JJ; Fauchais AL; Le Guern V; Larroche C; Dernis E; Guellec D; Cornec D; Sibilia J; Mariette X; Gottenberg JE; Meyer A
Rheumatology (Oxford); 2021 Feb; 60(2):675-681. PubMed ID: 32780813
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
